Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
{
"resourceType" : "MedicationStatement",
"id" : "PriorSystemicTherapyStatementExample",
"meta" : {
"profile" : [
🔗 "https://nshr-uat.sha.go.ke/fhir/StructureDefinition/nccp-prior-systemic-therapy-statement"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>5 years of adjuvant tamoxifen for ER+ breast cancer (2018–2023) prior to current recurrence</p></div>"
},
"status" : "completed",
"category" : {
"coding" : [
{
"system" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/med-clinical-category-cs",
"code" : "HORMONAL-THERAPY",
"display" : "Hormonal Therapy"
}
]
},
"medicationCodeableConcept" : {
"coding" : [
{
"system" : "https://nshr-uat.sha.go.ke/fhir/CodeSystem/generic-products-cs",
"code" : "TAMOXIFEN",
"display" : "Tamoxifen"
}
]
},
"subject" : {
🔗 "reference" : "Patient/example-patient"
},
"effectivePeriod" : {
"start" : "2018-03-01",
"end" : "2023-02-28"
},
"reasonReference" : [
{
🔗 "reference" : "Condition/example-condition"
}
],
"note" : [
{
"text" : "Completed 5 years of adjuvant tamoxifen. Switched to letrozole following menopause in 2021."
}
]
}